A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by activating the mother’s immune system to produce defence proteins, which are then transferred to the foetus through the placenta. This mother-derived protection provides newborns with instant defence from the point of delivery, precisely when they are highly susceptible to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a two-week gap is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if administered later in the third trimester.
- Nearly 85% protection when immunised four weeks before birth
- Maternal antibodies passed through placenta safeguard newborns from day one
- Coverage achievable with 2-week gap before early delivery
- Vaccination during the third trimester still offers significant infant protection
Compelling evidence from the latest research
The effectiveness of the pregnancy RSV vaccine has been confirmed through a comprehensive study conducted across England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that six-month period, providing strong and reliable evidence of the vaccine’s actual performance. The study’s conclusions have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scale of this research provides healthcare professionals and prospective parents with confidence in the vaccine’s proven efficacy across diverse populations and circumstances.
The results reveal a striking picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV during the study period, with the vast majority being infants whose mothers had not received the vaccination. This clear distinction emphasises the vaccine’s vital importance in reducing the risk of serious illness in newborns. The drop in hospital admissions above 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.
Methodology and scope of study
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection levels and hospitalisations. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to identify the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology assessed practical outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine works when delivered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the risks
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.
The infection triggers inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to feed and breathe effectively. Parents frequently observe their babies visibly struggling, their chests heaving as they attempt to draw adequate oxygen into their weakened respiratory system. Whilst most infants improve through clinical support, a small but significant proportion perish from respiratory syncytial virus complications annually, making immunisation programmes a vital health service objective for safeguarding the most vulnerable and youngest people in our communities.
- RSV causes inflammation in lungs, resulting in serious respiratory problems in infants
- Approximately half of newborns catch the infection in their first few months of life
- Symptoms span from mild colds to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV each year
- A small number of infants succumb to RSV related complications each year in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme began in 2024, health officials have highlighted the significance of pregnant women getting their jab at the best time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that the timing is essential for ensuring newborns receive the strongest possible immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery offers approximately 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies via the placenta.
The messaging from public health bodies stays clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has provided reassurance to pregnant women that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This adaptable strategy recognises the practical demands of pregnancy whilst ensuring strong protection for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional differences in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have attained greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and access to the jab. These regional differences reflect differences across medical facilities, engagement approaches, and community involvement initiatives, though the national data shows consistently strong protection regardless of geographical location.
- NHS trusts deploying varied communication campaigns to reach pregnant women
- Geographic variations in vaccine uptake rates in different parts of England necessitate strategic intervention
- Community health services adapting programmes to meet specific population needs
Practical implications and parental perspectives
The vaccine’s remarkable effectiveness translates into concrete gains for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this protective measure, the 80% decrease in admissions means thousands of infants protected against critical disease. Parents no longer face the distressing scenario of seeing their babies struggle for breath or struggle to eat, symptoms that define critical RSV illness. The vaccine has substantially transformed the picture of neonatal lung health, giving expectant mothers a active means to shield their youngest infants during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection caused severe brain damage, the vaccine’s accessibility carries significant emotional significance. His mother’s advocacy for the jab underscores the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to women in pregnancy in their third trimester, changing what was once an unavoidable seasonal threat into a manageable health risk.